Loading...

PE anti-mouse CD8a Antibody

Pricing & Availability
Clone
53-6.7 (See other available formats)
Regulatory Status
RUO
Other Names
T8, Lyt2, Ly-2
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
1_53-6dot7_PE_041106
C57BL/6 mouse splenocytes were stained with CD8 (clone 53-6.7) PE (filled histogram) or rat IgG2a, κ PE isotype control (open histogram).
  • 1_53-6dot7_PE_041106
    C57BL/6 mouse splenocytes were stained with CD8 (clone 53-6.7) PE (filled histogram) or rat IgG2a, κ PE isotype control (open histogram).
  • 2_53-67_PE_CD8a_Antibody_2_040122
    C57BL/6 mouse splenocytes were stained with CD8a (clone 53-6.7) PE (solid line) or rat IgG2a, κ PE isotype control (dashed line).
See PE spectral data
Cat # Size Price Quantity Check Availability Save
100707 50 µg $37
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100708 200 µg $107
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD8, also known as Lyt-2, Ly-2, or T8, consists of disulfide-linked α and β chains that form the α(CD8a)/β(CD8b) heterodimer and α/α homodimer. CD8a is a 34 kD protein that belongs to the immunoglobulin family. The CD8 α/β heterodimer is expressed on the surface of most thymocytes and a subset of mature TCR α/β T cells. CD8 expression on mature T cells is non-overlapping with CD4. The CD8 α/α homodimer is expressed on a subset of γ/δ TCR-bearing T cells, NK cells, intestinal intraepithelial lymphocytes, and lymphoid dendritic cells. CD8 is an antigen co-receptor on T cells that interacts with MHC class I on antigen-presenting cells or epithelial cells. CD8 promotes T cell activation through its association with the TCR complex and protein tyrosine kinase lck.

Product Details
Technical data sheet

Product Details

Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse thymus or spleen
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The CD8a antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

Clone 53-6.7 antibody competes with clone 5H10-1 antibody for binding to thymocytes3. The 53-6.7 antibody has been reported to block antigen presentation via MHC class I and inhibit T cell responses to IL-2. This antibody has also been used for depletion of CD8a+ cells. Additional reported applications (for the relevant formats) include: immunoprecipitation1,3, in vivo and in vitro cell depletion2,10,15, inhibition of CD8 T cell proliferation3, blocking of cytotoxicity3,4, immunohistochemical staining5,6 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, and spatial biology (IBEX)29,30. Clone 53-6.7 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays or in vivo studies (Cat No. 100746).

Application References

(PubMed link indicates BioLegend citation)
  1. Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IHC, IP)
  2. Hathcock KS. 1991. Current Protocols in Immunology. 3.4.1. (Deplete)
  3. Takahashi K, et al. 1992. P. Natl. Acad. Sci. USA 89:5557. (Block, IP)
  4. Ledbetter JA, et al. 1981. J. Exp. Med. 153:1503. (Block)
  5. Hata H, et al. 2004. J. Clin. Invest. 114:582. (IHC)
  6. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045. (IHC)
  7. Shih FF, et al. 2006. J. Immunol. 176:3438. (FC)
  8. Kamimura D, et al. 2006. J. Immunol. 177:306.
  9. Bouwer HGA, et al. 2006. P. Natl. Acad. Sci. USA 103:5102. (FC, Deplete)
  10. Kao C, et al. 2005. Int. Immunol. 17:1607. PubMed
  11. Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed
  12. Rasmussen JW, et al. 2006. Infect. Immun. 74:6590. PubMed
  13. Lee CH, et al. 2009. Clin. Cancer Res. PubMed
  14. Geiben-Lynn R, et al. 2008. Blood 112:4585. (Deplete) PubMed
  15. Kingeter LM, et al. 2008. J. Immunol. 181:6244. PubMed
  16. Guo Y, et al. 2008. Blood 112:480. PubMed
  17. Andrews DM, et al. 2008. J. Virol. 82:4931. PubMed
  18. Britschqui MR, et al. 2008. J. Immunol. 181:7681. PubMed
  19. Kenna TJ, et al. 2008. Blood 111:2091. PubMed
  20. Jordan JM, et al. 2008. Infect. Immun. 76:3717. PubMed
  21. Todd DJ, et al. 2009. J. Exp. Med. 206:2151. PubMed
  22. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  23. Medyouf H, et al. 2010. Blood 115:1175. PubMed
  24. Riedl P, et al. 2009. J. Immunol. 183:370. PubMed
  25. Apte SH, et al. 2010. J. Immunol. 185:998. PubMed
  26. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  27. del Rio ML, et al. 2011. Transpl. Int. 24:501. (FC) PubMed
  28. Cui L, et al. 2015. J Control Release. 206:220. PubMed
  29. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  30. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Xu C, et al. 2017. Biochemical and Biophysical Research Communications. 10.1016/j.bbrc.2017.05.071. PubMed
  2. Manrique-Rincón A, et al. 2017. Front Immunol. 10.3389/fimmu.2017.01150. PubMed
  3. Lee YT, et al. 2018. PLoS One. 13:e0190868. PubMed
  4. Zhang J, et al. 2018. Nature. 553:91. PubMed
  5. Jia H, et al. 2018. Int J Oncol. 53:949. PubMed
  6. Kagoya Y, et al. 2018. Nat Commun. 9:1915. PubMed
  7. Echevarría-Vargas IM, et al. 2018. EMBO Mol Med. 10:e8446. PubMed
  8. Habib S, et al. 2018. Infect Immun. 86:e00019. PubMed
  9. Zhou T, et al. 2018. Mol Med Rep. 17:4883. PubMed
  10. Yuzhu Hou et al. 2018. Immunity. 49(3):490-503 . PubMed
  11. Liu Y, et al. 2018. Cancer Cell. 33:480. PubMed
  12. Iwamoto H et al. 2018. Cell metabolism. 28(1):104-117 . PubMed
  13. Xia Y, et al. 2018. Cell. 175:1059. PubMed
  14. Lu Y, et al. 2018. Cancer Cell. 33:1048. PubMed
  15. Dietmar Herndler‐Brandstetter et al. 2018. Immunity. 48(4):716-729 . PubMed
  16. Zhang W, et al. 2019. Oncol Lett. 17:815. PubMed
  17. Perry JSA, et al. 2018. Immunity. 48:923. PubMed
  18. Kong XF, et al. 2018. Nat Immunol. 19:973. PubMed
  19. Subramanian K, et al. 2019. Nat Microbiol. 4:62. PubMed
  20. Li J, et al. 2019. JCI Insight. 5. PubMed
  21. Lee CG, et al. 2019. JCI Insight. 4:5. PubMed
  22. Misumi I et al. 2019. Cell Rep. 27(2):514-524 . PubMed
  23. Eisemann T, et al. 2019. Front Oncol. 9:187. PubMed
  24. Misumi I et al. 2019. Cell Rep. 27(5):1387-1396 . PubMed
  25. Cai Y, et al. 2019. Cell Rep. 27:3034. PubMed
  26. Naing A et al. 2019. Cell reports. 26(5):1242-1257 . PubMed
  27. Uchimura T et al. 2018. Immunity. 49(6):1049-1061 . PubMed
  28. Paris J et al. 2019. Cell Stem Cell. 25(1):137-148 . PubMed
  29. Niemann J, et al. 2019. Nat Commun. 10:3236. PubMed
  30. Clemente–Casares X, et al. 2017. Immunity. 47:974. PubMed
  31. Radulovic V, et al. 2020. Cell Reports. 27(10):2826-2836.e5.. PubMed
  32. Du Q, et al. 2019. Front Microbiol. 10:2050. PubMed
  33. Chen X, et al. 2019. Med Sci Monit. 25:5389. PubMed
  34. van Montfoort N, et al. 2018. Cell. 175:1744. PubMed
  35. Becher J, et al. 2018. Dev Cell. 47:592. PubMed
  36. Jin X, et al. 2019. Mol Cell. 73:22:00. PubMed
  37. Yuan X, et al. 2017. Elife. 6:e29540. PubMed
  38. Oliveira AC et al. 2017. eLife. 6 pii: e30883. PubMed
  39. Morabito KM, et al. 2017. Mucosal Immunol. 0.795138889. PubMed
  40. Guo C, et al. 2017. Methods Mol Biol. 1709:345. PubMed
  41. Frazier T, et al. 2018. Adipocyte. 0.41875. PubMed
  42. van Erp EA, et al. 2019. Viruses. 0.811111111. PubMed
  43. Yamashita M, et al. 2019. Cell Stem Cell. 25:357. PubMed
  44. Wong YC, et al. 2019. J Virol. 93:e01154-19. PubMed
  45. Huang X, et al. 2019. Cancer Immunol Res. 1.388888889. PubMed
  46. Burr ML, et al. 2019. Cancer Cell. 36:385. PubMed
  47. Meyer LK, et al. 2019. J Clin Invest. 130:863. PubMed
  48. Yoshida H, et al. 2019. Cell. 176:897. PubMed
  49. Davidson S, et al. 2020. Cell Reports. 31(7):107628. PubMed
  50. Tsuchiya N, et al. 2020. Cell Reports. 29(1):162-175.e9.. PubMed
  51. Demircioglu F, et al. 2020. Nat Commun. 11:1290. PubMed
  52. Hsu SPC, et al. 2020. J Neurooncol. 146:417. PubMed
  53. Zhao B, et al. 2020. Nat Commun. 11:908. PubMed
  54. Chaurasiya S, et al. 2020. Oncoimmunology. 9:1729300. PubMed
  55. Rana A, et al. 2020. Front Immunol. 11:536. PubMed
  56. Frodermann V, et al. 2019. Nat Med. 25:1761. PubMed
  57. Peng L, et al. 2020. Transl Lung Cancer Res. 0.892361111. PubMed
  58. Parhi L, et al. 2020. Nat Commun. 2.721527778. PubMed
  59. Thomas AM, et al. 2020. Journal of Cellular Physiology. 235(6):5120-5129.. PubMed
  60. Kamata T, et al. 2020. Cell Reports. 31(12):107802. PubMed
  61. Loh Z, et al. 2020. PLOS Pathogens. 16(7):e1008651. PubMed
  62. Marchingo JM, et al. 2020. eLife. 9:e53725.. PubMed
  63. Liang J, et al. 2020. Sci Adv. 6:eabc3646. PubMed
  64. He Y, et al. 2020. Sci Adv. 6:eaba7589. PubMed
  65. Paul S, et al. 2018. Appl Microbiol Biotechnol. 102:8895. PubMed
  66. Hu Q, et al. 2018. Nat Biomed Eng. 0.660416667. PubMed
  67. Rodriguez-Sosa M, et al. 2004. Infect Immun. 72:4552. PubMed
  68. Lo W, Allen D 2012. Nat Immunol. 13:880. PubMed
  69. Zhao X, et al. 2013. Int Immunopharmacol. 17:793. PubMed
  70. Wong L, et al. 2013. J Biol Chem. 288:35170. PubMed
  71. Chen X, et al. 2009. Hum Immunol. 70:79. PubMed
  72. N'guessan P, et al. 2011. Antioxid Redox Signal. 15:1693. PubMed
  73. LeBlanc P, et al. 2014. J Biol Chem. 289:7777. PubMed
  74. Zhu E, et al. 2014. J Immunol. 192:5599. PubMed
  75. Burrack K, et al. 2015. J Immunol. 194:678. PubMed
  76. Lu X, et al. 2015. J Immunol. 194:2011. PubMed
  77. Shade K, et al. 2015. J Exp Med. 212:457. PubMed
  78. Sharma S, et al. 2015. J Immunol. 194:5529. PubMed
  79. Ibrahim M, et al. 2016. J Evid Based Complementary Altern Med. 21: 171 - 176. PubMed
  80. Yang E, et al. 2015. Acta Biochim Biophys Sin. 47: 588-596. PubMed
  81. Kmieciak M, et al. 2011. J Vis Exp. 47: 2381. PubMed
  82. Wong J, et al. 2015. Elife. 3: 07839. PubMed
  83. Sido J, et al. 2015. J Leukoc Biol. 98: 435-447. PubMed
  84. Flesch I, et al. 2015. J Immunol. 195: 2263-2272. PubMed
  85. Wu Y, et al. 2015. J Immunol. 195: 2612-2623. PubMed
  86. Burrack K, et al. 2015. PLoS Pathog. 11: e1005191. PubMed
  87. Zhang Y, et al. 2015. PLoS Pathog. 11: e1005167. PubMed
  88. Spinner C, et al. 2015. Sci Rep. 5:16269. PubMed
  89. Schuldt N, et al. 2015. PLoS One. 10: 0145762. PubMed
  90. Pai M, et al. 2016. JPEN J Parenter Enteral Nutr. 40: 383 - 391. PubMed
  91. Chou T, et al. 2016. Nat Commun. 7:11904. PubMed
  92. Wang Y, et al. 2016. Sci Rep. 6:31881. PubMed
  93. Li B, Schmidt N 2016. PLoS One. 11: 0162427. PubMed
  94. Felker A, Croy B 2016. J Leukoc Biol. 100: 645 - 655. PubMed
  95. Angela M, et al. 2016. Nat Commun. 7:13683. PubMed
  96. Aguilera T, et al. 2016. Nat Commun. 7:13898. PubMed
  97. Hu HJ, et al. 2020. Cell Death Dis. 1.168055556. PubMed
  98. Qi T, et al. 2020. Cell Rep. 33:108452. PubMed
  99. Kang YA, et al. 2020. J Exp Med. 217:00:00. PubMed
  100. Montel-Hagen A, et al. 2020. Cell Rep. 33:108320. PubMed
  101. Cai Z, et al. 2020. Cell Rep. 31:107816. PubMed
  102. Li J, et al. 2020. FASEB J. 34:3091. PubMed
  103. Aguilera TA, et al. 2020. Clin Cancer Res. 26:2972. PubMed
  104. Wei Z, et al. 2021. Nat Commun. 0.805555556. PubMed
  105. Kovacs SB, et al. 2021. STAR Protoc. 2:100244. PubMed
  106. Melo-Silva CR, et al. 2021. PLOS Pathogens. 17(5):e1009593. PubMed
  107. Tran S, et al. 2020. Immunity. 53(3):627-640.e5. PubMed
  108. Xu C, et al. 2020. Immunity. 53(2):417-428.e4. PubMed
  109. Si J, et al. 2020. Cancer Cell. 38(4):551-566.e11. PubMed
  110. Plumlee CR, et al. 2020. Cell Host Microbe. 29(1):68-82.e5. PubMed
  111. Heyde A, et al. 2021. Cell. 184(5):1348-1361.e22. PubMed
  112. Han C, et al. 2021. Cell Reports. 34(6):108706. PubMed
  113. Lv K, et al. 2021. Cell Stem Cell. 28(7):1275-1290.e9. PubMed
  114. Levine LS, et al. 2021. Immunity. 54(4):829-844.e5. PubMed
  115. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  116. Yu K, et al. 2021. Cell Reports. 35(12):109273. PubMed
  117. Sun L, et al. 2021. Cancer Cell. 39:1361. PubMed
  118. Ene CI, et al. 2020. Neuro Oncol. 639:22. PubMed
  119. Liu Y, et al. 2020. Oncol Lett. 2369:20. PubMed
  120. Ren D, et al. 2020. Am J Cancer Res. 2851:10. PubMed
  121. Bonavita E, et al. 2020. Immunity. 1215:53. PubMed
  122. Onai N, et al. 2020. Int J Mol Sci. :22. PubMed
  123. Zeng A, et al. 2020. Oncol Rep. . PubMed
  124. Monaghan KL, et al. 2020. J Vis Exp. . PubMed
  125. Fedele C, et al. 2021. J Exp Med. 218: . PubMed
  126. Wang X, et al. 2021. Theranostics. 11:209. PubMed
  127. Wang F, et al. 2021. Neoplasia. 23:281. PubMed
  128. Rodríguez L, et al. 2021. Biomolecules. 11: . PubMed
  129. Zhang Z, et al. 2021. Oncoimmunology. 10:1912472. PubMed
  130. Wang Y, et al. 2021. Front Immunol. 12:654463. PubMed
  131. James OJ, et al. 2021. Nat Commun. 12:4290. PubMed
  132. Yang Z, et al. 2021. Nat Commun. 12:4299. PubMed
  133. Wei JL, et al. 2021. J Immunother Cancer. 9: . PubMed
  134. Cartwright ANR, et al. 2021. Cancer Immunol Res. 9:470. PubMed
  135. Grigsby SM, et al. 2021. Cancers (Basel). 13:. PubMed
  136. Watson MJ, et al. 2021. Nature. 591:645. PubMed
  137. Shi GN, et al. 2021. Ther Adv Med Oncol. 13:1758835920987056. PubMed
  138. Lu Y, et al. 2021. Gastroenterology. 161:575. PubMed
  139. Sugita Y, et al. 2021. Oncol Rep. 45:. PubMed
  140. Li H, et al. 2021. Nat Commun. 12:2773. PubMed
  141. Bates PD, et al. 2021. Front Immunol. 12:668307. PubMed
  142. Tsai SJ, et al. 2021. J Biol Chem. 297:101266. PubMed
  143. Cho K, et al. 2021. iScience. 24:103117. PubMed
  144. Chen R, et al. 2021. Front Oncol. 11:743050. PubMed
  145. Lawson H, et al. 2021. Stem Cell Reports. 16:2784. PubMed
  146. Liu W, et al. 2021. Cell Mol Immunol. 18:2660. PubMed
  147. Pilones KA, et al. 2020. Cancer Immunol Res. 8:1054. PubMed
  148. Ren J, et al. 2021. Theranostics. 11:304. PubMed
  149. Kline JM, et al. 2021. J Biol Chem. :100373. PubMed
  150. Li J, et al. 2020. Development. :. PubMed
  151. Lin J, et al. 2021. Nat Commun. 12:5321. PubMed
  152. Bristow CL, et al. 2021. Front Oncol. 11:739080. PubMed
  153. Edwards CJ, et al. 2021. Br J Cancer. . PubMed
  154. Sun C, et al. 2022. J Adv Res. 35:71. PubMed
  155. Koide S, et al. 2022. iScience. 25:103603. PubMed
  156. Anderson AE, et al. 2022. NPJ Regen Med. 7:6. PubMed
  157. Wang X, et al. 2022. Elife. 11:. PubMed
  158. Dang Y, et al. 2022. Cancer Cell Int. 22:88. PubMed
  159. Chavez JS, et al. 2022. Cells. 11:. PubMed
  160. Sun F, et al. 2022. Cell Death Dis. 13:181. PubMed
  161. Dourcy M, et al. 2020. Mucosal Immunol. 13:799. PubMed
  162. Pastor Arroyo EM, et al. 2022. Clin Sci (Lond). 136:557. PubMed
  163. Baranwal G, et al. 2021. Physiol Rep. 9:e15094. PubMed
  164. Wu G, et al. 2021. Nat Cancer. 2:1170. PubMed
  165. Zhang M, et al. 2022. iScience. 25:104490. PubMed
  166. Manukian G, et al. 2021. Int J Radiat Oncol Biol Phys. 110:1341. PubMed
  167. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  168. Wu S, et al. 2021. Nat Cancer. 2:189. PubMed
  169. Chen C, et al. 2021. J Virol. 95:e0082921. PubMed
  170. Zhu J, et al. 2021. Cancer Cell Int. 21:529. PubMed
  171. Qin Y, et al. 2021. Cell Rep. 37:109968. PubMed
  172. Lin J, et al. 2021. Cancer Immunol Res. 9:1413. PubMed
  173. Barsoumian HB, et al. 2022. Cancers (Basel). 14:. PubMed
  174. Xu Z, et al. 2022. Cell Death Dis. 13:502. PubMed
  175. Wang B, et al. 2022. Nat Commun. 13:3821. PubMed
  176. Sá da Bandeira D, et al. 2022. Cell Rep. 40:111114. PubMed
  177. Hu G, et al. 2022. Cell Death Dis. 13:640. PubMed
  178. Jia L, et al. 2022. Front Immunol. 13:897879. PubMed
  179. Zhong W, et al. 2022. Nat Commun. 13:4390. PubMed
  180. Glaubitz J, et al. 2022. Nat Commun. 13:4502. PubMed
  181. Yang H, et al. 2022. Nutrients. 14:. PubMed
  182. Papafragkos I, et al. 2022. Front Immunol. 13:889075. PubMed
  183. Sun Y, et al. 2022. iScience. 25:104846. PubMed
  184. Schreiber K, et al. 2020. Cancer Immunol Res. 8:192. PubMed
  185. Moutuou MM, et al. 2020. Methods Mol Biol. 2111:267. PubMed
  186. Sng XYX, et al. 2020. J Immunol. 204:3108. PubMed
  187. Skirecki T, et al. 2020. JCI Insight. 5:. PubMed
  188. Ebina-Shibuya R, et al. 2021. Elife. 10:. PubMed
  189. Uchida A, et al. 2021. J Inflamm Res. 14:3089. PubMed
  190. Lee S, et al. 2021. JCI Insight. 6:. PubMed
  191. Glaros V, et al. 2021. Immunity. 54:2005. PubMed
  192. Gawish R, et al. 2022. Elife. 11:. PubMed
  193. Shen DD, et al. 2022. Mol Cancer. 21:75. PubMed
  194. Wu SY, et al. 2022. Mol Cancer. 21:84. PubMed
  195. Schloss MJ, et al. 2022. Nat Immunol. 23:605. PubMed
  196. Li Z, et al. 2022. Nat Commun. 13:1845. PubMed
  197. Yang N, et al. 2022. Nat Commun. 13:2336. PubMed
  198. Yang R, et al. 2022. Front Pharmacol. 13:774440. PubMed
  199. Tian X, et al. 2022. Front Immunol. 13:875236. PubMed
  200. Schnoegl D, et al. 2022. Front Immunol. 13:909270. PubMed
  201. Chan WF, et al. 2022. Nat Commun. 13:5582. PubMed
  202. Li H, et al. 2022. Theranostics. 12:6422. PubMed
  203. Zhang S, et al. 2022. Cell Death Dis. 13:844. PubMed
  204. Dong M, et al. 2022. J Immunother Cancer. 10:. PubMed
  205. Han Y, et al. 2022. Int J Biol Sci. 18:5653. PubMed
  206. Kim DK, et al. 2022. Nat Commun. 13:6292. PubMed
  207. Li Z, et al. 2022. Nat Commun. 13:6321. PubMed
  208. Quijano-Rubio A, et al. 2022. Nat Biotechnol. Online ahead of print. PubMed
  209. Mauduit O, et al. 2022. Front Immunol. 13:1011125. PubMed
  210. Gomez S, et al. 2022. J Immunother Cancer. 10:. PubMed
  211. Zelenka T, et al. 2022. Nat Commun. 13:6954. PubMed
  212. Diao L, et al. 2022. iScience. 25:105511. PubMed
  213. Thomas R, et al. 2021. Immunology. 163:478. PubMed
  214. Xue G, et al. 2021. Cancer Cell. 39:1610. PubMed
  215. Zveik O, et al. 2022. Glia. 70:1191. PubMed
  216. Liu H, et al. 2022. Cancer Immunol Res. 10:1028. PubMed
  217. Silva Pereira S, et al. 2022. Elife. 11: . PubMed
  218. del Rio ML, et al. 2022. Front Immunol. 13:887348. PubMed
  219. Lin G, et al. 2022. Int J Immunopathol Pharmacol. 36:3946320221117933. PubMed
  220. Zheng D, et al. 2023. Bioact Mater. 22:567. PubMed
  221. Wang H, et al. 2022. J Nanobiotechnology. 20:513. PubMed
  222. He Y, et al. 2022. Front Immunol. 13:986202. PubMed
  223. Hao J, et al. 2022. Cell Rep. 41:111804. PubMed
  224. Shi C, et al. 2023. Nat Nanotechnol. 18:86. PubMed
  225. Horkova V, et al. 2023. Nat Immunol. 24:174. PubMed
  226. An HW, et al. 2022. Cell Rep. 41:111878. PubMed
  227. Kumpunya S, et al. 2023. Front Immunol. 13:1010764. PubMed
  228. Huseni MA, et al. 2023. Cell Rep Med. 4:100878. PubMed
  229. Glaubitz J, et al. 2023. Gut. :. PubMed
  230. Lin J, et al. 2023. Nat Commun. 14:224. PubMed
  231. Lu T, et al. 2023. Cancer Immunol Immunother. :. PubMed
  232. Takacs GP, et al. 2023. Front Immunol. 13:993444. PubMed
  233. Pan C, et al. 2022. Cell Mol Immunol. 19:516. PubMed
  234. Kodali S, et al. 2022. J Immunol. 208:1085. PubMed
  235. He Y, et al. 2022. Adv Healthc Mater. 11:e2200905. PubMed
  236. Sugitani N, et al. 2022. Cell Rep. 40:111371. PubMed
  237. Shi X, et al. 2022. Proc Natl Acad Sci U S A. 119:e2208506119. PubMed
  238. Zhu C, et al. 2022. Chemotherapy. 67:211. PubMed
  239. Chen Y, et al. 2022. Am J Cancer Res. 12:5286. PubMed
  240. Sparbier CE, et al. 2023. Nat Cell Biol. 25:258. PubMed
  241. Swan SL, et al. 2023. Front Immunol. 14:1085547. PubMed
  242. Wang F, et al. 2023. Int J Mol Sci. 24:. PubMed
  243. Tan J, et al. 2023. Acta Pharm Sin B. 13:632. PubMed
  244. Wang JX, et al. 2023. JCI Insight. 8:. PubMed
  245. Wu Y, et al. 2023. Nat Cancer. 4:382. PubMed
  246. Dang YZ, et al. 2023. Neoplasma. 70:123. PubMed
  247. Tang C, et al. 2023. Nat Commun. 14:1493. PubMed
  248. Hao H, et al. 2023. Nat Biomed Eng. . PubMed
  249. Tao Q, et al. 2023. Microbiol Spectr. :e0522922. PubMed
  250. Fukuzaki Y, et al. 2023. iScience. 26:106340. PubMed
  251. del Rio ML, et al. 2023. Front Immunol. 14:1113858. PubMed
  252. Liu H, et al. 2023. Breast Cancer Res. 25:43. PubMed
  253. Fu S, et al. 2023. Nat Commun. 14:2248. PubMed
  254. Qin T, et al. 2023. Virol J. 20:75. PubMed
  255. Li T, et al. 2023. Nat Commun. 14:2498. PubMed
  256. Oh J, et al. 2023. Nat Commun. 14:3278. PubMed
  257. Ye S, et al. 2023. Front Oncol. 13:1202750. PubMed
RRID
AB_312746 (BioLegend Cat. No. 100707)
AB_312747 (BioLegend Cat. No. 100708)

Antigen Details

Structure
Ig superfamily, CD8α chain, 34 kD
Distribution

Most thymocytes, T cell subset, some NK cells, lymphoid dendritic cells

Function
Co-receptor for TCR
Ligand/Receptor
MHC class I molecule
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Zamoyska R. 1994. Immunity 1:243.
3. Ellmeier W, et al. 1999. Annu. Rev. Immunol. 17:523.

Gene ID
12525 View all products for this Gene ID
UniProt
View information about CD8alpha on UniProt.org

Related FAQs

What type of PE do you use in your conjugates?
We use R-PE in our conjugates.
Go To Top Version: 2    Revision Date: 01/21/2014

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login/Register
Remember me
Forgot your password? Reset Password
Request an Account